Sign In
Buy WXXWY
$8.21
-0.700 (-7.86%)
At Close: Jun 03, 2026
WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally
09:30pm, Sunday, 08'th Feb 2026
SHANGHAI, Feb. 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), announced it has been awarded a Platinum Medal by the EcoVadis Sustainability Rating, marking the third year the company has received
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announc
Short Interest in WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Drops By 70.7%
03:11am, Wednesday, 28'th Jan 2026
WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) was the target of a large drop in short interest during the month of January. As of January 15th, there was short interest totaling 22,35
SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology an
WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Sees Large Growth in Short Interest
01:19am, Friday, 16'th Jan 2026
WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totaling 76,332 shares, a growth of
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
11:00pm, Wednesday, 14'th Jan 2026
Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects 209 new integrated projects in 2025 set a new record, with approximately 50%
WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
08:05pm, Wednesday, 14'th Jan 2026
WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
10:07pm, Monday, 12'th Jan 2026
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing f
WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing
08:09am, Monday, 12'th Jan 2026
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a s
WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
10:57pm, Sunday, 04'th Jan 2026
WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sus
WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure
11:30pm, Tuesday, 23'rd Dec 2025
HONG KONG , Dec. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) has once again raised the bar for sustainability commitment and transparency. The company has been honored by the Hong Kong ESG Repo
WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security
04:30am, Friday, 19'th Dec 2025
SHANGHAI , Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named to the CDP "A" lists for both Climate Change and Water Security for 2025, underscoring its leadership
WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority
03:46am, Tuesday, 02'nd Dec 2025
DOHA, Qatar , Dec. 2, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has signed a strate
WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
08:30pm, Tuesday, 21'st Oct 2025
The only company from pharmaceutical industry selected for inclusion in the Index Also included in HSI ESG Index and Hang Seng ESG 50 Index Green CRDMO solution provider with outstanding sustainabilit
WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan
05:30am, Monday, 20'th Oct 2025
SHANGHAI , Oct. 20, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been honored wit
